Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 15 Dec 23 424B5 Prospectus supplement for primary offering
- 14 Dec 23 424B5 Prospectus supplement for primary offering
- 26 May 23 424B5 Prospectus supplement for primary offering
- 7 Dec 22 424B5 Prospectus supplement for primary offering
- 6 Dec 22 424B5 Prospectus supplement for primary offering
- 17 Dec 21 424B5 Prospectus supplement for primary offering
- 16 Dec 21 424B5 Prospectus supplement for primary offering
- 9 Dec 21 424B5 Prospectus supplement for primary offering
-
24 Mar 21 S-3ASR Automatic shelf registration
SNDX similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-3 of our report dated March 11, 2021 relating to the financial statements of Syndax Pharmaceuticals, Inc., appearing in the Annual Report on Form 10-K of Syndax Pharmaceuticals, Inc. for the year ended December 31, 2020. We also consent to the reference to us under the heading “Experts” in such Registration Statement.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 24, 2021